Phase I study of CC-5013 (lenalidomide, NSC 703813, IND 70116) in pediatric patients with relapsed/refractory solid tumors or myelodysplastic syndromes.

Trial Profile

Phase I study of CC-5013 (lenalidomide, NSC 703813, IND 70116) in pediatric patients with relapsed/refractory solid tumors or myelodysplastic syndromes.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2012

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 May 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top